RHEZ

DRUG2 trials

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.

Conditions

Pulmonary TB

Phase 1

A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis

CompletedNCT03678688

Otsuka Pharmaceutical Development & Commercialization, Inc.Pulmonary TB

Start: 2018-10-18End: 2022-03-11Updated: 2023-11-18

Phase 2

Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB

CompletedNCT05221502

Otsuka Pharmaceutical Development & Commercialization, Inc.Pulmonary TB

Start: 2022-04-12End: 2024-05-19Updated: 2026-08-12

Related Papers

Efficacy and safety of a 4-month quabodepistat, delamanid, and bedaquiline regimen for drug-susceptible pulmonary tuberculosis: a multicentre, open-label, randomised, proof-of-concept, non-inferiority, phase 2b/c trial.

2026-05-29

Safety, pharmacokinetics, and early bactericidal activity of quabodepistat in combination with delamanid, bedaquiline, or both in adults with pulmonary tuberculosis: a randomised, active-controlled, open-label trial.

2024-11-263 citations

Quabodepistat in combination with delamanid and bedaquiline in participants with drug-susceptible pulmonary tuberculosis: protocol for a multicenter, phase 2b/c, open-label, randomized, dose-finding trial to evaluate safety and efficacy

Trials2024-01-199 citations

Sputum lipoarabinomannan (LAM) as a biomarker to determine sputum mycobacterial load: exploratory and model-based analyses of integrated data from four cohorts.

2022-04-0211 citations